(1 - 9 von 9
)
AEZS.OQ - AEterna Zentaris Inc. (USA) | Stock Price & Latest News |...
www.reuters.com
Nicola Ammer: Senior Vice President - Clinical Development, Chief Medical Officer. Guenther Grau: Vice President - Finance. › AEZS
AETERNA ZENTARIS ANNOUNCES EMA DECISION TO ACCEPT A
www.globenewswire.com
– Modifications recommended for some key elements of planned safety and efficacy Study P02 – – Modifications to the outline of Study P02 requested to...
Aeterna Zentaris Announces Completion of Patient Recruitment in...
www.wallstreet-online.de
– Study P01 is the first of two studies as agreed with the EMA in the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone...
Aeterna Zentaris Announces Publication of GHD Management
www.globenewswire.com
Nicola Ammer, Chief Medical Officer, Aeterna Zentaris, on the guidelines update. “This encouraging news supports our belief in the strong ...
History of Changes for Study: NCT ClinicalTrials.gov
clinicaltrials.gov
Central Contact Person: Nicola Ammer, MD Telephone: + Study Officials: Dan Atar, MD Principal Investigator › history
Stockwatch
www.stockwatch.com
No Hype - just the Facts. Your complete source of news and realtime quotes from the TSX, TSX-V, CSE, Montreal, Nasdaq, NYSE, Amex and OTC Markets.
AETERNA ZENTARIS ANNOUNCES EMA DECISION TO ACCEPT A MODIFICATION TO...
www.einnews.com
— ... exciting advancement for our pediatric development program,” commented, Dr. Nicola Ammer, Chief Medical Officer of Aeterna Zentaris. › pr_news
Aeterna Zentaris Announced Presentation of Positive Results
www.globenewswire.com
- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in …s Data from this...
macimorelin | Semantic Scholar
www.semanticscholar.org
Beate M. Klaus, Richard Sachse, Nicola Ammer, Nicky Kelepouris, Vlady Ostrow; Growth hormone & IGF research : official journal… 2020; Corpus ID: ...
sortiert nach Relevanz / Datum